Research & Development PENAO-01 clinical trial completed 26 patients with advanced solid tumours enrolled at three Australian hospitals. Patient with anaplastic astrocytoma had stable disease at 6 mg/m2/day over 10 cycles (30 weeks). Eight dose levels investigated. Maximum Tolerated Dose not reached. R&D Pipeline A Phase II clinical trial is planned to investigate combination therapies and doses in ~50 patients with Breast Cancer or Non-Small Cell Lung Cancer (NSCLC) at hospitals across Australia and China. Nonclinical studies contracted in Australia will add value and potentially accelerate the approval process. Development and optimisation of manufacturing operations.